Evidence map›Paper›PMID 39155753›Full record

ArticleEuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology2024

Determinants of adverse outcomes following patent foramen ovale closure in elderly patients.

Julio I Farjat-Pasos, Paul Guedeney, Eric Horlick, Jeremie Abtan, Luis Nombela-Franco, Benjamin Hibbert, Lars Sondergaard, Xavier Freixa, Jean-Bernard Masson, Ignacio Cruz-González and 19 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. The patent foramen ovale does not spontaneously close in patients aged 60.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Julio I Farjat-PasosCardiology Department, Quebec Heart and Lung Institute, Québec, QC, Canada.
Paul GuedeneySorbonne Université, ACTION Study Group, INSERM UMRS_1166, Institut de Cardiologie (AP-HP), Paris, France.
Eric HorlickCardiology Department, Toronto General Hospital, Toronto, ON, Canada.
Jeremie AbtanCardiology Department, Bichat-Claude-Bernard Hospital, Paris, France.
Luis Nombela-FrancoCardiovascular Institute, Hospital Clínico San Carlos, IdISSC, Madrid, Spain.
Benjamin HibbertCardiology Department, Ottawa Heart Institute, Ottawa, ON, Canada.
Lars SondergaardCardiology Department, Heart Centre, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Xavier FreixaCardiology Department, Hospital Clinic of Barcelona, Barcelona, Spain.
Jean-Bernard MassonCardiology Department, University of Montreal Health Centre, Montreal, QC, Canada.
Ignacio Cruz-GonzálezCardiology Department, University Hospital of Salamanca, IBSAL, CIBER-CV, Salamanca, Spain.
Rodrigo Estévez-LoureiroCardiology Department, University Hospital Complex of Vigo, Vigo, Spain.
Laurent FarouxCardiology Department, Reims University Hospital, Reims, France.
Ashish H ShahSection of Cardiology, Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada.
Lusine AbrahamyanCardiology Department, Toronto General Hospital, Toronto, ON, Canada.
Jules MesnierCardiology Department, Bichat-Claude-Bernard Hospital, Paris, France.
Adrián JerónimoCardiovascular Institute, Hospital Clínico San Carlos, IdISSC, Madrid, Spain.
Omar Abdel-RazekCardiology Department, Ottawa Heart Institute, Ottawa, ON, Canada.
Troels Højsgaard JørgensenCardiology Department, Heart Centre, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Mike Al AsmarCardiology Department, University of Montreal Health Centre, Montreal, QC, Canada.
Samuel SitbonCardiology Department, Bichat-Claude-Bernard Hospital, Paris, France.
Mohammed AbalhassanCardiology Department, Ottawa Heart Institute, Ottawa, ON, Canada.
Mathieu RobichaudCardiology Department, Quebec Heart and Lung Institute, Québec, QC, Canada.
Christine HoudePediatric Cardiology Department, Centre Hospitalier Universitaire de Québec, Québec, QC, Canada.
Mélanie CôtéCardiology Department, Quebec Heart and Lung Institute, Québec, QC, Canada.
Angel ChamorroNeuroscience Department, Hospital Clinic of Barcelona, Barcelona, Spain.
Sylvain LanthierNeurovascular Program and Research Center, Hôpital du Sacré-Coeur-de-Montréal, Montreal, QC, Canada.
Steve VerreaultNeurovascular Department, Centre Hospitalier Universitaire de Québec, Québec, QC, Canada.
Gilles MontalescotSorbonne Université, ACTION Study Group, INSERM UMRS_1166, Institut de Cardiologie (AP-HP), Paris, France.
Josep Rodés-CabauCardiology Department, Quebec Heart and Lung Institute, Québec, QC, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLimited data are available on transcatheter patent foramen ovale (PFO) closure outcomes in the elderly.

aimsThrough this study, we aimed to determine the incidence and predictors of adverse events (recurrent cerebrovascular events [CVE] and atrial fibrillation [AF]) post-PFO closure in older patients with cryptogenic events.

methodsThis multicentre international study included patients over 60 years undergoing PFO closure for cryptogenic thromboembolic events. A dedicated database compiled baseline, procedural, and follow-up data. Competing risk and adjusted outcome predictor analyses were conducted.

resultsA total of 689 patients were included (median age 65 years, 41.2% female, mean Risk of Paradoxical Embolism [RoPE] score 4.5). The procedural success rate was 99.4%. After a median follow-up of 2 (interquartile range 1-5) years, 66 patients (9.6%) had died. CVE and stroke rates were 1.21 and 0.55 per 100 patient-years, respectively. Diabetes (hazard ratio [HR] 3.89, 95% confidence interval [CI]: 1.67-9.07; p=0.002) and atrial septal aneurysm (ASA; HR 5.25, 95% CI: 1.56-17.62; p=0.007) increased the CVE risk. New-onset AF occurred at a rate of 3.30 per 100 patient-years, with 51.3% within one month post-procedure. Older age (HR 1.05 per year, 95% CI: 1.00-1.09; p=0.023) and the absence of hypertension (HR 2.04, 95% CI: 1.19-3.57; p=0.010) were associated with an increased risk of AF.

conclusionsOlder patients undergoing PFO closure had a relatively low rate of CVE and new-onset AF after a median follow-up of 2 years. The presence of diabetes, ASA, and a more advanced age determined an increased risk of adverse clinical events. These factors may be considered in the clinical decision-making process regarding PFO closure in this challenging population.

Indexed as

Atrial FibrillationCardiac CatheterizationForamen Ovale, PatentAgedAged, 80 and overAge FactorsEmbolism, ParadoxicalFemaleHumansIncidenceMaleMiddle AgedRisk FactorsSeptal Occluder DeviceStrokeTreatment Outcome

Identifiers

PMID39155753
PMCPMC11317834

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.